Neurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.
Neurocrine: the neuroscience cash engine still has to broaden beyond one franchise
NASDAQNBIXCoverage BootstrapNeurocrine Biosciences, Inc.
Thesis summary
Neurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.
View article
Discuss the thesis
0 commentsCommenting requires active membershipBecome a member
Attack the thesis, not the person.Add evidence when challenging claims.No pump, spam, or low-effort comments.
No comments yet. Start the discussion with evidence, a question, or a bear case.